| Oct 29 |
BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings and Revenue Estimates
|
| Oct 29 |
BioMarin Pharmaceutical Inc. 2024 Q3 - Results - Earnings Call Presentation
|
| Oct 29 |
BioMarin: Q3 Earnings Snapshot
|
| Oct 29 |
BioMarin Pharmaceutical Non-GAAP EPS of $0.91 beats by $0.12, revenue of $745.74M beats by $42.43M
|
| Oct 29 |
BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook
|
| Oct 28 |
BioMarin Pharmaceutical Q3 2024 Earnings Preview
|
| Oct 24 |
Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate
|
| Oct 24 |
BioMarin Pharmaceutical (BMRN): Hedge Funds Back Biotech Leader Amid Record Revenue Growth
|
| Oct 23 |
Blueprint Medicines (BPMC) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
| Oct 22 |
BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
|
